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Chemotherapy is a common treatment for leukemia. Ruthenium complexes have shown potential utility in
chemotherapy and photodynamic therapy. The identification of new chemotherapeutics agents is critical for further
progress in the treatment of leukemia. Ruthenium complexes generally have lower toxicities compared to cisplatin
attributed to their specific accumulation in cancer tissues. Based on these evidences, in the present work we studied
the cytotoxic activity of the ruthenium(III) compound cis-tetraammine(oxalato)ruthenium(III) dithionate - {cis-[Ru(C2O4)
(NH3)4]2(S2O6)} against human chronic myelogenous leukemia cells (K-562) tumor cell line. The tested compound
induces cell death in a dose and time dependent manner on K-562 cells. It is found that the effect was improved
linearly while prolonging the incubation time. Compared to the cell cycle profiles of untreated cells, flow cytometric
analysis indicated the sub-G1 arresting effect of ruthenium compound on K-562 cells. In our study, {cis-[Ru(C2O4)(NH3)4]
2(S2O6)} shows a significant increase in tailed cells in any of the concentrations tested compared with negative control.
Consequently, the concentration of {cis-[Ru(C2O4)(NH3)4]2(S2O6)} might be associated cytotoxicity with direct effect on
K-562 cells DNA. Thus, it can be deducted that ruthenium-based compounds present selectivity to enter both tumor
and normal cells. Additional studies are needed to determine the molecular mechanisms of the active components
and to evaluate the potential in vivo anticancer activity of the cis-tetraammine(oxalato)ruthenium(III) dithionate.
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Immunomodulatory activity; Apoptosis1. Introduction
Leukemia is a major type of cancer affecting a significant
segment of the population, and especially children. In
fact, leukemia is the most frequent childhood cancer,
with 26% of all cases, and 20% mortality (Canadian Cancer
Society/National Cancer Institute of Canada 2005). The
American Cancer Society (ACS) estimated that 47,150
new cases of leukemia would be diagnosed in the United
States in 2012, whereas about 23,540 adults and children
would die of leukemia during 2012 (American Cancer
Society 2009).* Correspondence: silveiralacerda@gmail.com
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in any medium, provided the original work is pAlthough the incidence rate for this disease remains
relatively unchanged, some success has fortunately been
attained in its treatment. But even if the success of clinical
trials in identifying new agents and treatment modalities
has been significant, current treatments have many limita-
tions related to their side effects and the development of
acquired drug resistance (Robert and Jarry 2003) The new
therapeutic agents thus needed should be more active and
produce less side effects and they also should act through a
mechanism different from that of cytotoxic agents already
used (Menezes et al. 2007; Silveira-Lacerda et al. 2009).
Chemotherapy is a common treatment for leukemia
(Ge et al. 2009). In general the therapy uses a number of
different anticancer drugs, which destroy cancer cells by
preventing them from growing and dividing rapidly.
Unfortunately, a number of the body’s normal, non-n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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blood-clotting platelets, and cells of the gastrointestinal
mucosa) also divide rapidly and are harmed by chemo-
therapy (Ge et al. 2009; Kim et al. 2002). The side effects
of chemotherapy hamper many normal activities of pa-
tients undergoing treatment (Kim et al. 2002).
The preparations of metallo complexes with potential
antitumor activity has been one of the main targets of tran-
sition metal chemistry since Rosenberg’s discovery of cis-
platin {cis-diamminedichloridoplatinum(II), cis-[Pt(NH3)
2Cl2]} cytotoxic activity in the 1960s (Rosenberg et al.
1965). In 1978, cisplatin was approved as the first platinum
based drug for the oncology treatment, although several
negative side-effects (nephrotoxicity, neurotoxicity, nausea,
etc.) had been induced on treated patients (Kelland and
Farrell 2000). Nevertheless, cisplatin was followed by
carboplatin {cis-diammine-1,1′ -cyclobutanedicarboxylate
platinum(II), [Pt(NH3)2(cbdc)], approved in 1985} and oxa-
liplatin {1R,2R-diamminocyclohexaneoxalatoplatinum(II),
[Pt(dach)(ox)], approved in 1996}, which met requirements
of improving antitumor activity and reducing disadvan-
tages of cisplatin, carboplatin and oxaliplatin represent the
second, and third platinum-based drug generations, re-
spectively ((Kelland and Farrell 2000; Štarha et al. 2009).
Nowadays, not only platinum-bearing complexes are
extensively studied with the aim to broaden a spectrum of
transition metal-based complexes which could be used in
the treatment of cancer (Štarha et al. 2009).
In addition to the other metal complexes cisplatin
have been developed using heavy metals. For example,
gold complexes have been developed for the treatment of
rheumatoid arthritis, silver complexes as anti-microbial
agents, antimony complexes for the treatment of leish-
maniasis, vanadium(IV) complexes as antiviral and
antidiabetic agents, arsenic trioxide (Trisenox) for the
treatment of acute promyelocytic leukaemia, and metal-
activated bleomycin for the treatment of Hodgkin’s
lymphoma and testicular cancer. Transition-metal-based
therapeutic agents currently under clinical trials include
third generation antitumor platinum complexes such as li-
posomal cisplatin (Lipoplatin), satraplatin, and picoplatin,
the antimalarial ferrocene–quinoline conjugate ferroquine
(Lung et al. 2013).
Rhodium and Iridium has also been used for the synthe-
sis of these metal complexes, as they allow greater select-
ivity and affinity molecules. The iridium (III) already
shows results inhibiting TNF-α in HepG2 line through a
hydrophobic binding (Meggers 2009; Leung et al. 2012).
These metal complexes possess many advantages that
make them suitable for the development of new thera-
peutic agents and compounds of ruthenium has been
highlighted because ruthenium complexes have shown po-
tential utility in chemotherapy and photodynamic therapy
(Clarke 2003; Ronconi and Sadler 2007). Rutheniumcomplexes generally have lower toxicities compared to cis-
platin attributed to their specific accumulation in cancer
tissues (Sava et al. 1998). In vitro and in vivo studies show
high anticancer activity of ruthenium complexes and some
of them are currently undergoing clinical trials (Jakupec
et al. 2005; Hartinger et al. 2006).
The identification of new chemotherapeutics agents is
critical for further progress in the treatment of leukemia.
In comparison to the platinum(II) antitumor complexes
currently used in the clinic, ruthenium compounds offer
potentially reduced toxicity, a novel mechanism of action,
the prospect of non-cross-resistance, and a different
spectrum of activity (Clarke 2003). The reduced toxicity
is in part due to the ability of ruthenium complexes to
mimic the binding of iron to molecules of biological
significance, exploiting the mechanisms that the body
has evolved for non-toxic transport of iron (Frasca
et al. 2001). This reduced toxicity, together with non-
cross-resistance in cisplatin-resistant cancer cells, is
particularly attractive attributes of these complexes
(Allardyce et al. 2003).
Based on these evidences, in the present work we studied
the cytotoxic activity of the ruthenium(III) compound
cis-tetraammine(oxalato)ruthenium(III) dithionate {cis-
[Ru(C2O4)(NH3)4]2(S2O6)} against human chronic mye-
logenous leukemia (K-562) tumor cell line.2. Results
2.1 The cis-[Ru(C2O4)(NH3)4]2(S2O6) compound reduces
viability of K-562 cells
Results derived from Trypan blue staining essay revealed
that K-562 cells cultured with concentrations 40 and 150
μM of ruthenium(III) compound showed significant re-
duction of proliferation after 72 h of exposition, with via-
bilities ranging from 88.2% to 55.6% when treated with 40
μM for 24 and 72 h; and 76.2% to 26.7% when treated
with 150 μM for 24 and 72 h Figure 1.2.2 The cis-[Ru(C2O4)(NH3)4]2(S2O6) compound presents
cytotoxic activity towards K-562 tumor cell lines
To verify the cytotoxic activity of cis-[Ru(C2O4)(NH3)4]2
(S2O6) on K-562 cell lines, tumor cells were cultured for
24 and 48 h in the presence of different concentrations of
ruthenium compound. MTT reduction assay revealed that
ruthenium compound produced concentration and time-
dependent cytotoxicity effects on K-562 cells. The results
Figure 2b show that the ruthenium(III) compound in-
duced low [22.4% (24 h) to 28.2% (48 h) and 29.8% (24 h)
to 35.7% (48 h) for concentrations 10 and 40 μM, respect-
ively] to up [44% (24 h) and 53% (48 h) for concentration
150 μM] of cytotoxic activity against K-562. After incuba-
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Figure 1 Cytotoxic activity of cis-tetraammine(oxalato)ruthenium(III) dithionate compound towards K-562 cell line. The data show the
mean ± S.D. (standard deviation) of three independent experiments [GraphPad Prism version 4.02 for Windows (GraphPad Software, San Diego,
California, USA)]. *p < 0.05 vs. negative control.
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K-562 cells as verified by DNA ladder analysis
The significantly reduced number of K-562 cells in the
presence of cis-tetraammine(oxalato)ruthenium(III) dithio-
nate on previous assays suggests that this compound could
be inducing cell death via apoptosis. To examine pro-
apoptotic properties of the ruthenium(III) compound,
K-562 cells were cultured in the presence of different
concentrations of ruthenium compound (from 0.15–
150 μM) and then DNA ladder analysis was performed
via agarose gel electrophoresis. K-562 cells cultured inFigure 2 Anti-proliferative activity of cis-tetraammine(oxalato)rutheni
The data show the mean ± S.D. (standard deviation) of three independent
Software, San Diego, California, USA)]. *p < 0.05 vs. negative control. # = 0%the presence of ruthenium compound but not in
medium alone presented DNA fragmentation (Data not
shown).
2.4 The cis-[Ru(C2O4)(NH3)4]2(S2O6) presents genotoxic
effects against K-562 tumor cells
The alkaline comet assay has been used to assess the pos-
sible genotoxicity of cis-tetraammine(oxalato)ruthenium
(III) dithionate against K-562 cells. Results indicate that
K-562 tumor cells cultured with ruthenium(III) com-
plex show a significant increase in DNA damage indexum(III) dithionate compound towards K-562 cell line (a and b).
experiments [GraphPad Prism version 4.02 for Windows (GraphPad
. Dotted line = IC50 concentration for 48 h of treament.
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control, in a dose-dependent manner (Figure 3). Results
show an average DNA damage index of 59 for 10 μM, 140
for 40 μM, 176 for 150 μM when K-562 tumor cells were
exposed to ruthenium(III) for 24 h; and 108 for 10 μM,
154 for 40 μM and 197 for 150 μM, for 48 h of exposition.
Thus, the concentration of cis-[Ru(C2O4)(NH3)4]2(S2O6)
might be associated cytotoxicity with direct effect on K-
562 cells DNA (p < 0.05).
2.5 The cis-[Ru(C2O4)(NH3)4]2(S2O6) increased the number
of K-562 tumor cells in sub-G1 phase, an indicative of
apoptosis
The cell cycle distribution of K-562 cells treated with
different concentrations of ruthenium compound (from
1.5–150 μM) for 24, 48 and 72 h revealed a prominent
increasing of cells on sub-G1 phase at concentration 40
and 150 μM and reduction on G0/1, S and G2/M
phases. Figure 4 shows that treatment with 40 and 150
μM of cis-[Ru(C2O4)(NH3)4]2(S2O6) for 24, 48 and 72 h
caused an increase in the proportion of cells in the sub-
G1-peak correlating with fewer cells in G0/G1, S and
G2/M. The fraction of sub-G1 cells increased from
14.5% in the control to 59% at 24 h; 10.7% in the control
to 68.6% at 48 h; 15.5% in the control to 84.7% for 72 h
on cells treated with 40 μM of cis-tetraammine(oxalato)
ruthenium(III) dithionate. The same effect was observed
when K-562 tumor cells were treated with 150 μM of ru-
thenium(III) compound. The ruthenium(III) compound
caused a minor S phase accumulation after incubation at

























Figure 3 Induction of DNA strand breaks of K-562 cells cultured in th
figure represent the mean ± S.D. of 3 independent experiments using tripli3 Discussion
Apoptosis is an active physiological process resulting in
cellular self-destruction that involves specific morphological
and biochemical changes in the nucleus and cytoplasm
(Kostova 2006). Agents that suppress the proliferation of
malignant cells by inducing apoptosis may represent a
useful mechanistic approach to both cancer chemopre-
vention and chemotherapy. While many anticancer agents
have been developed, unfavourable side effects and resist-
ance are serious problems (Panchal 1998). Since the intro-
duction of cisplatin in cancer therapy, metal complexes
and organometallic compounds have been gaining import-
ance in oncology (Panchal 1998; Sanna et al. 2002). Metal-
based compounds increase the possibility of developing
molecules better-suited for binding to specific biological
targets (Sanna et al. 2002; Hartinger et al. 2006).
Ruthenium complexes appear particularly promising; al-
though they exhibit lower cytotoxicity as compared to cis-
platin, they are better tolerated in vivo (Sanna et al. 2002;
Hartinger et al. 2006; Menezes et al. 2007). Research on
bioactive ruthenium(II) complexes is very active (Chen
and Wong 2008). These studies have led to the develop-
ment of ruthenium based anticancer agents (Yan et al.
2005; Ang and Dyson 2006; Hartinger et al. 2006). Re-
search groups of Sadler, Dyson, Keppler and Reedijk have
synthesized a remarkably large number of Ru(II)/Ru(III)
organometallic complexes that are being tested for anti-
cancer activity. Ruthenium complexes are slitly cytotoxic
but do not affect normal cells significantly. Ruthenium
drugs are very promising candidates for novel cancer ther-
apy, with two drugs already in clinical trials, NAMI-A and
KP1019 (Cocchietto and Sava 2000; Zorzet et al. 2001;48h








e presence of cis-[Ru(C2O4)(NH3)4]2(S2O6) compound. Results in the
cate samples. *Increased above control at p < 0.05.
Figure 4 Cell cycle profile histogram of K-562 cells treated with cis-tetraammine(oxalato)ruthenium(III) dithionate. PI fluorescence was
analyzed by flow cytometry (FACS Canto II, BD Biosciences, San José, CA, USA).
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use of new organometallics for the treatment of various
cancers and the development of safer and more effective
therapeutic agents (Panchal 1998; Silveira-Lacerda et al.
2009). In the present work, we studied the cytotoxic activity
of cis-tetraammine(oxalato)ruthenium(III) dithionate cyto-
toxicity towards human chronic myelogenous leukemia
(K-562) tumor cell line.
The antiproliferative activity of cis-tetraammine(oxalato)
ruthenium(III) dithionate, a ruthenium-based complex, have
been evaluated in vitro against human leukemia (K-562)Table 1 Cell cycle analysis of K-562 tumor cell lines after treatm
Control Ru 1.5 μM
24 h Mean ± S.D. Mean ± S.D
Sub-G0/G1 14.45 ± 0.6 30.20 ± 2.1
G1 27.20 ± 0.3 25.25 ± 2.1
S 19.05 ± 0.1 27.50 ± 1.1
G2 14.10 ± 0.1 14.85 ± 0.8
48 h
Sub-G0/G1 10.70 ± 0.7 24.65 ± 1.1
G1 35.65 ± 0.6 31.70 ± 1.0
S 21.35 ± 0.4 30.05 ± 0.8
G2 10.00 ± 1.4 12.50 ± 0.3
72 h
Sub-G0/G1 15.50 ± 16.0 34.50 ± 1.4
G1 35.45 ± 10.1 31.75 ± 0.5
S 20.05 ± 4.7 23.80 ± 0.6
G2 7.45 ± 0.8 9.30 ± 0.4
The percentage of cells in G0/G1, S, G2/M and sub-G1 was analyzed using ModFit L
cells at each phase of the cell cycle (G0/G1, S, G2/M). Data represent mean values ±
results shown are representative of at least three similar experiments. *p < 0.05 vs. ccells using trypan blue and MTT assay. Inhibition of cell
proliferation is an important potency indicator for chemo-
therapeutic drugs. As shown in Figures 1 and 2a and b, the
tested compound induces cell death in a dose and time
dependent manner on K-562 cells. It is found that the effect
was improved linearly while prolonging the incubation time.
The determined IC50 values of this complex, 18.28 μM
(Figure 2a), is considerably the same of those of the com-
mercially used antineoplastic drugs cisplatin (IC50 = 11 μM)
and oxaliplatin (IC50 = 18 μM) on the same tumor cell line
(Štarha et al. 2009). These results corroborate previousent with cis-tetraammine(oxalato)ruthenium(III) dithionate
Ru 10 μM Ru 40 μM Ru 150 μM
Mean ± S.D Mean ± S.D Mean ± S.D
31.20 ± 1.4 59.00 ± 2.3 68.90 ± 1.8
19.55 ± 0.9 11.50 ± 1.7 14.75 ± 0.9
29.10 ± 1.1 18.60 ± 2.1 11.40 ± 0.8
18.10 ± 0.7 9.15 ± 1.6 4.00 ± 0.1
40.55 ± 2.6 68.60 ± 1.1 67.60 ± 0.1
14.85 ± 2.6 8.35 ± 0.4 19.30 ± 0.4
26.35 ± 2.1 14.35 ± 0.9 9.75 ± 0.2
17.05 ± 2.3 7.85 ± 0.1 2.95 ± 0.1
45.95 ± 1.1 84.70 ± 0.3 70.50 ± 2.8
17.05 ± 0.2 4.95 ± 0.1 18.70 ± 1.0
26.05 ± 0.6 7.20 ± 0.6 9.25 ± 1.6
10.50 ± 0.3 3.10 ± 0.1 1.45 ± 0.2
T software (Verity Software House, Topsham, ME, USA). Percentage of viable
SD of triplicate samples or a histogram for each condition and cell type. The
ontrol.
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towards tumor cells such as human Jurkat, HeLa and SK-
BR-3, and murine S-180 and A-20 tumor cell lines (Frasca
et al. 2001; Silveira-Lacerda et al. 2009).
For ruthenium(II) complexes as methylimidazole (RMC1)
he also found having cytotoxicity of 17.34 mg mL-1 for
A549, 18.89 mg mL-1 for A375 and 20.25 mg mL-1 for Hep
G2, respectively. The same compound exhibits cytotoxicity
of 51.59 mg mL-1 for HBE (basal lineage), as well as
demonstrating that the compound RMC1 ruthenium II
(Yang et al. 2012). The complex [Ru(phen)2(ƥ-MOPIP)]2+
can effectively inhibit proliferation of the A375 cell line with
a low IC50 (5.9 ± 1.1 mM). [Ru(bpy)2(dppn)]
2+ exhibits high
cytotoxicity against human HT-29 and MCF-7 cancer cell
lines comparable to that of cisplatin induces cell death in a
dose and time dependent manner (Schatzschneider et al.
2008), and [Ru(dmp)2(DBHIP)]
2+ can effectively induce
apoptosis of the BEL-7402 cell line (Liu et al. 2010).
The lower general toxicity of ruthenium compounds
compared to platinum drugs has been attributed to the
ability of ruthenium compounds to specifically accumulate
in cancer tissues. The higher specificity of these compounds
for their targets may also be linked to their selective uptake
by the tumor compared with healthy tissue and to selective
activation by reduction to cytotoxic species within the
tumor (Bergamo et al. 1999; Allardyce et al. 2003; Clarke
2003).
Ruthenium-chloro complexes tend to undergo hydrolysis
in aqueous media leading to the generation of cationic
Ru–OH2 complexes capable of reacting with DNA with
greater ease than the corresponding chloro complexes
(Melchart et al. 2007; Bacac et al. 2004; Hotze et al. 2004).
The hydrolyzed complexes interact with the N7 of guanine
in DNA duplexes leading to disruption of the structure of
genetic material (Chen et al. 2003).
To explore the mechanisms of the cytotoxic effects
produced by cis-tetraammine(oxalato)Ruthenium(III) dithio-
nate, drug-induced changes in cell cycle distribution were
examined. Compared to the cell cycle profiles of untreated
cells, flow cytometric analysis indicated the sub-G1 arresting
effect of ruthenium compound on K-562 cells, as ruthenium
(III) dithionate already induced a 48.2% increase in the num-
ber of sub-G0/G1 cells after a 48 h incubation. The ruthe-
nium(III) compound caused a minor S phase accumulation
after incubation at concentrations of 40 and 150 μM for all
periods of exposition Figure 4. Treatment with 40 μM of
cis-[Ru(C2O4)(NH3)4]2(S2O6) induced respectively a 1.7-fold,
2.2-fold and 2.4-fold increase in the number of sub-G0/G1
cells when compared to control for 24, 48 and 72 h,
respectively Table 1.
Furthermore, another important biochemical sign of
apoptosis was studied: DNA laddering and fragmentation
(data not shown), possibly representing DNA cleavage
into oligonucleosomal fragments through activation of thecysteine protease caspase-3, which is involved in the
proteolytic cleavage of key downstream proteins such as
poly (ADP-ribose) polymerase (PARP) (Bortner et al. 1995;
Clarke and Stubbs 1996). This process ultimately results in
DNA fragmentation and apoptotic death (Bortner et al.
1995). Although this type of binding has been suggested to
mimic, to some extent, cisplatin-induced DNA crosslinking,
other types of damage may exist that dominate or contribute
to the biological activity of this drug prototype.
Several studies have been using this test to corroborate
the results obtained in other assays. In the present study,
results derived from DNA laddering assay did not show
K-562 DNA fragmentation, instead the results shows DNA
integrity and even differences on DNA content. Is import-
ant note that this data does not corroborate with more
sensitive techniques such as flow cytometry and comet
assay, used in this work. These techniques confirmed that
the ruthenium(III) compound interfere on cell cycle and
induces cells to enter apoptosis. Thus, we can infer that the
technique of DNA gel electrophoresis is not best assay to
assess the degradation of genome DNA.
The present study also evaluated the DNA-damaging
effects detected by the alkaline version of the comet assay
in K-562 cancer cells. This assay has been used as a test to
predict the risk to develop certain diseases (renal cell
carcinoma, cancers of the bladder, esophagus, and lung)
due to susceptibility of the individual to DNA damage
(Ribeiro et al. 2009). The in vitro comet assay is proposed
as an alternative to cytogenetic assays in early genotoxicity/
photogenotoxicity screening of drug candidates as well as
for neurotoxicity (Witte et al. 2007).
The alkaline comet assay has been used to assess the
genotoxicity of chemicals, environmental exposures to
carcinogens, toxins, and physical agents both in vitro and
in vivo (Trzeciak et al. 2000; Sekihashi et al. 2002). This
method was also used to measure DNA repair capacity in
live cells (Banath et al. 1998) and acellular systems (Dusinská
et al. 2004).
In our study, cis-[Ru(C2O4)(NH3)4]2(S2O6) shows a
significant increase in tailed cells in any of the concentra-
tions tested compared with negative control (Figure 3).
Consequently, the concentration of cis-[Ru(C2O4)(NH3)4]2
(S2O6) might be associated cytotoxicity with direct effect
on K-562 cells DNA. Thus, it can be deducted that
ruthenium-based compounds present selectivity to enter
both tumor and normal cells. It is known that all the body
cells present transferrin receptors, particularly tumor cells,
in which these receptors are found in higher numbers.
Due to these features, higher quantities of ruthenium
complexes penetrate tumor tissue, reduce ruthenium(III)
to ruthenium(II) and binding to DNA (guanine), and pro-
mote strand breaks (Clarke and Stubbs 1996; Lebwohl
and Canetta 1998; Sava and Bergamo 2000; Katsaros and
Anagnostopoulou 2002; Galanski et al. 2003; Desoize
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this compound might enter normal cells, because ruthenium
(III) complexes are activated only by its reduction when it
finds an environment with high concentration of glutathione,
low pH, and occurrence of hypoxia. It is very common to
find tumor cells presenting these conditions since it is known
that these cells have high levels of glutathione and oxygen
consumption when the nutrients are quickly used due to
their accelerated development promoting hypoxia (Sava and
Bergamo 2000). Consequently, these cells need more glycoli-
tic energy, which increases the level of lactic acid in the
tissues and causes a decrease in the media pH. It is worth
emphasizing that ruthenium(III) compounds can be used as
pro-drugs that are activated by in vivo reduction to ruthe-
nium(II) (Desoize 2004; Sava and Bergamo 2000).
Broadening the chemotherapeutic arsenal depends on un-
derstanding existing agents with a view toward developing
new modes of attack. Indeed, few of the organometallics
compounds may function in a manner analogous to
cisplatin, which appears to bend DNA by cross-linking
adjacent guanines, thereby causing a class of DNA binding
proteins to adhere to the site. Overall, the broad class of
ruthenium(III) antitumor agents appears to differ from
cisplatin by favoring interstrand rather than intrastrand
cross-links (Clarke et al. 1999). In agreement with this
hypothesis, it was demonstrated that NAMI-A induced
apoptosis in the ECV304 transformed human endothelial
and KP1019 in colorectal carcinoma cell lines via activation
of caspase-3 and DNA fragmentation (Bortner et al. 1995;
Nunez et al. 1998; Kapitza et al. 2005).
Despite the resounding success of cisplatin and closely
related platinum antitumor agents, the movement of other
transition-metal antitumor agents toward the clinic has
been exceptionally slow (Clarke et al. 1999). Non-Platinum
chemotherapeutic metallopharmaceuticals hold much pro
mise for the future, and needs to be actively explored in a
large variety of tumor types in combination therapies.
Besides the already well established NAMI-A and KP-1019
activities on gastrointestinal, breast, prostate, and ovarian
cancers (Pluim et al. 2004; Bergamo and Sava 2007),
development as a potential anti-tumor drug.Figure 5 Chemical structure of cis-tetraammine(oxalato)ruthenium(III)4 Conclusions
The present results indicate that cis-[Ru(C2O4)(NH3)4]2
(S2O6) is worthy of further development as a potential anti-
tumor drug that could be used in the treatment of
leukemia. Thus, additional studies are needed to determine
the molecular mechanisms of the active components and
to evaluate the potential in vivo anticancer activity of the
cis-tetraammine(oxalato)ruthenium(III) dithionate.
5 Material and methods
5.1 Synthesis of cis-[Ru(C2O4)(NH3)4]2(S2O6)
The cis-[Ru(C2O4)(NH3)4]2(S2O6) complex (Figure 5), was
synthesized at the Universidade Federal de Uberlândia
(UFU, Minas Gerais, Brazil) following a standard protocol
described by Pereira et al. (2009). The compound was
characterized by electronic spectra at room temperature
with the HP 8453 spectrophotometer with diodes arrange-
ment, interfacing a compatible PC HP Vectra XM, using
quartz cells. Carbon and hydrogen microanalyses were
performed by the staff of the Analitical Centre of the
Chemistry Institute of Universidade de São Paulo (USP, São
Paulo, Brazil).
5.2 Cell culture
The human chronic myelogenous leukemia (K-562) cell
line (ATCC number CCL-243™) was obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA). The cells were cultured in RPMI 1640 medium
(pH 7.2–7.4) supplemented with 100U mL-1 penicillin G,
100 μg mL-1 streptomycin, 2 mM L-glutamine, 1.5 g L-1
sodium bicarbonate, 4.5 g L-1 glucose, 10 mM HEPES,
1.0 mM sodium pyruvate and 10% fetal calf serum (FCS)
(all reagents were obtained from Gibco, Grand Island, NY,
USA) at 37°C, 5% CO2 and humidified atmosphere.
The cells were disposed into 96 well plates (1 × 105 cells/
well) and cultured in RPMI 1640 medium. Cells were
harvested at specified intervals and the number of cells
per well was determined by cell counting with a hemo-
cytometer (Neubauer chamber). Briefly, tumor cells were
aspirated, washed in sterile PBS and an aliquot of the cell
suspension was put in Trypan Blue 1% (m/v) (Sigma-dithionate.
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dilutions with > 95% of viable cells were included in the
posteriors analysis.
5.3 Cell citotoxicity (Trypan blue staining)
The citotoxicity of the K-562 cells was evaluated by the try-
pan blue exclusion assay. The tumor cells were incubated
for 24 h, 48 h and 72 h with different concentrations of the
tested ruthenium compound cis-[Ru(C2O4)(NH3)4]2(S2O6)
(from 0.015–32 μM) at 37°C. Additionally, Carboplatin
(50 μM) and Paclitaxel (25 μM) were applied as positive
control. After incubation, the cells were washed in PBS (pH
7.4) and suspended in a complete RPMI 1640 medium.
Then 40 μL of the trypan blue solution (0.4%, Sigma) and
10 μL of the cell suspension were mixed and after 5 min
the percentage of viable K-562 cells was evaluated under
brightfield optical microscope using a newbauer chamber.
The correlation between the viable cells (that excluded
trypan blue dye) and dead cells (stained cells) were assessed.
The results are presented as mean ± S.D. (standard
deviation) from three independent experiments.
5.4 Viability assay
Cytotoxic activity of cis-[Ru(C2O4)(NH3)4]2(S2O6) on K-
562 was measured by modified MTT assay (Mosmann
1983), which is based on the reduction of yellow 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) to dark-blue, insoluble formazan in mitochondria of
the living cells. The MTT assay was performed in 96-well
tissue culture plates (Nalge-Nunc, Rochester, NY, USA) as
follows: the cells (1 × 105/well) were seeded in tissue culture
plates and incubated with the different concentrations of
ruthenium compound (from 0.15–150 μM) dissolved in a
total volume of 100 μL/well for 24 h and 48 h at 37°C and
5% CO2. The cells incubated with medium only served as a
control. Following the exposure to the tested substances,
the cells were incubated with 10 μL of MTT solution
(5 mg mL-1) (Sigma-Aldrich, St. Louis, MO, USA) for 3 h.
The microplates were then centrifuged (300 × g/15 min/10°C)
and the culture media were discarded. Afterwards 200 μl
of PBS/20% of SDS (lauryl sulfate) solution (Sigma-
Aldrich, USA) was added to each well to stop the reaction
and plates were kept in the dark overnight. After the next
12 h, the absorbance of dissolved formazan was measured by
a Stat Fax 2100 microplate reader (Awareness Technology,
Palm City, FL, USA) at 565 nm. The cell viability was
expressed in% related to control (100% of viability). The
cytotoxic rate was calculated as follows: cytotoxicity (%) =
[1 – (absorbance of the treated wells) / (absorbance of the
control wells)] × 100%. The cytotoxic effect of the tested
substances was determined in at least three independent
experiments, where each one of the culture plates con-
tained the wells with tested concentration in triplicate, the
wells with control (cells in medium) and the blank (culturemedium alone). The 50% inhibitory concentration (IC50)
value was determined using GraphPad Prism 4.02 for
Windows (GraphPad Software, San Diego, CA, USA).
5.5 DNA laddering assay
Briefly, 2 × 106 cells (K-562) were treated with different con-
centrations of cis-[Ru(C2O4)(NH3)4]2(S2O6) (from 0.15–
150 μM) for 24 h at 37°C and 5% CO2. Cells were harvested
and centrifuged at 300 × g/15 min/10°C and washed with
PBS. The cells were then ressuspended at a concentration of
1 × 106 cells mL-1 in an extraction buffer (1 mol Tris–HCl,
2 mol Na2EDTA, 0,5 g m L
-1 SDS) and treated with
20 mg L-1 RNase A at 37°C for 60 min, followed by incuba-
tion with proteinase K (100 mg L-1) at 37°C for 60 min. An
equal volume of saline solution (NaCl 6 M) was added to
the cells and centrifuged at 13,000 × g for 10 min. The
supernatant was collected and 2 volume ethanol (-20°C)
were added. The samples were centrifuged at 13,000 × g for
30 min at 4°C. The supernatant was then discarded and the
pellets dissolved in TE buffer (1×). The concentration
of DNA was detected using a UV spectrophotometer
(Beckman DU-640, USA). The DNA (5 μg/tube) was trans-
ferred to a 1.5% agarose horizontal gel, and electrophoresis
was performed at 100 V cm-1 for 90 min. The DNA in the
gels was visualized by ultraviolet transillumination after
staining with ethidium bromide (5 μg mL-1) using an
Omega® molecular imaging system (UltraLum Inc.,
Claremont, CA, USA).
5.6 Comet assay
An aliquot of from each K-562 culture was taken after 24
and 48 h incubation for the alkaline version of the comet
assay (Ribeiro et al. 2009). The compound cis-[Ru(C2O4)
(NH3)4]2(S2O6) was studied at different concentrations
(from 10–150 μM). Briefly, 300 μL of the cell suspension
was centrifuged for 5 min (500 rpm) in a refrigerated
microcentrifuge (Sorvall Legend Mach 1.6 R, Thermo
Fisher Scientific, Waltham, MA, USA). The resulting pellet
was homogenized with 80 μL of a low melting point
agarose (0.5%), spread onto microscope slides pre-coated
with a normal melting point agarose (1.5%), and covered
with a cover slip. After 5 min at 4°C, the cover slip was
removed, and the slides were immersed in cold lysis
solution [2.4 M NaCl, 100 mM ethylenediamine tetraacetic
acid (EDTA), 10 mM Tris, 10% DMSO, and 1% Triton-X,
pH 10] for 24 h.
After lysis, the slides were placed in an electrophoresis
chamber and covered with electrophoresis buffer (300 mM
NaOH per 1 mM EDTA, pH > 13) for a remaining 20 min
to allow DNA unwinding. The electrophoresis proceeded
for 20 min (25 V and 300 mA). Afterwards, the slides were
submerged for 15 min in a neutralization buffer (0.4 M
Tris– HCl, pH 7.5), dried at room temperature, and fixed
in 100% ethanol for 5 min. All the steps were conducted in
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staining was performed immediately before analysis using
ethidium bromide (20 μg mL−1). Slides were prepared in
duplicate, and 100 cells were screened per sample (50 cells
from each slide) in a fluorescent microscope (Leica Micro-
systems GmbH, Wetzlar, Germany) equipped with an
excitation filter of 515–560 nm and a barrier filter of
590 nm using a × 40 objective. The analyse nucleus was re-
alized in image analysis system software CometScore 15 ac-
cording to the migration of the fragments, as previously
proposed as follows: class 0 (no damage); class 1 (little dam-
age with a short tail length smaller than the diameter of the
nucleus); class 2 (medium damage with a tail length one or
two times the diameter of the nucleus); class 3 (significant
damage with a tail length between two and a half to three
times the diameter of the nucleus); and class 4 (significant
damage with a long tail of damage greater than three times
the diameter of the nucleus). A value (damage index, DI)
was assigned to each comet according to its class, according
to the following formula:
DI = (0 × n0) + (1 × n1) + (2 × n2) + (3 × n3) + (4 × n4), where
n = number of cells in each class analysed.
DI thus ranged from 0 (completely undamaged: 100
cells × 0) to 400 (with maximum damage; 100 cells × 4).
5.7 Cell cycle analysis by flow cytometry
In order to investigate the possible effect of the ruthenium
compound on cell cycle progression, K-562 cells were
treated with different concentrations of cis-[Ru(C2O4)(NH3)
4]2(S2O6) (from 1.5–150 μM) for 24, 28 and 72 h. Briefly,
5 × 105 cells were harvested by centrifugation, washed with
PBS, fixed with 70% (v/v) cold aqueous ethanol and stored
overnight at -20°C. The fixed cells were washed with PBS
and incubated with propidium iodide (PI; Sigma-Aldrich,
St. Louis, MO, USA) containing 0.05% RNase. Samples were
incubated at 4°C in the dark and analyzed by flow cytometry
(FACS CantoII, BD Biosciences, San José, CA, USA).
The percentage of cells in G1, S, G2 and sub-G1 was
analyzed using ModFit LT software (Verity Software House,
Topsham, ME, USA).
5.8 Statistical analysis
Three independent in vitro experiments were carried out.
Statistical results were expressed as the mean ± standard
deviation of the means obtained from triplicates of each
independent experiment. Correlation tests were performed
to determine the effects of concentration of ruthenium com-
plex on tumor cell lines. Statistical significance of differences
*(p < 0.05) as compared to untreated cells (control) was
evaluated by applying analysis of variance (ANOVA) and
Tukey or Dunnet’s post tests, when applicable. The IC50
(concentration that produces a 50% inhibitory effect on the
evaluated parameter) was graphically obtained from the
dose–response curves.Ethical Approval
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